Synergistic anti-cd47 therapy for hematologic cancers
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsIrving L. Weissman, Ravindra Majeti, Arash Ash Alizadeh, Mark P. Chao
Life of this patent
Estimating the term…
Abstract
Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2.
Claims16
A method for the treatment of a hematologic cancer in a patient, the method comprising:
- administering to said patient a synergistic combination of agents comprising a first agent that selectively inhibits or blocks CD47 and a second agent that selectively inhibits or blocks a second cancer associated cell surface marker.
A multispecific antibody specific for CD47 and for a cell surface marker associated with a hematologic cancer.
Dependencies are inferred from the claim text.